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InﬂammationThe heparan sulfate (HS) proteoglycan perlecan is a major component of basement membranes, plays a key
role in extracellular matrix (ECM) structure, interacts with growth factors and adhesion molecules, and
regulates the adhesion, differentiation and proliferation of vascular cells. Atherosclerosis is characterized by
chronic inﬂammation and the presence of oxidized materials within lesions, with the majority of protein
damage present on ECM, rather than cell, proteins. Weakening of ECM structure plays a key role in lesion
rupture, the major cause of heart attacks and strokes. In this study peroxynitrite, a putative lesion oxidant, is
shown to damage perlecan structurally and functionally. Exposure of human perlecan to peroxynitrite
decreases recognition by antibodies raised against both the core protein and heparan sulfate chains; dose-
dependent formation of 3-nitrotyrosine was also detected. These effects were modulated by bicarbonate and
reaction pH. Oxidant exposure resulted in aggregate formation, consistent with oxidative protein
crosslinking. Peroxynitrite treatment modiﬁed functional properties of perlecan that are dependent on
both the protein core (decreased binding of human coronary artery endothelial cells), and the HS chains
(diminished ﬁbroblast growth factor-2 (FGF-2) receptor-mediated proliferation of Baf-32 cells). The latter is
consistent with a decrease in FGF-2 binding to the HS chains of modiﬁed perlecan. Immunoﬂuorescence of
advanced human atherosclerotic lesions provided evidence for the presence of perlecan and extensive
formation of 3-nitrotyrosine epitopes within the intimal region; these materials showing marked co-
localization. These data indicate that peroxynitrite induces major structural and functional changes to
perlecan and that damage to this material occurs within human atherosclerotic lesions.thiazoline-6-sulphonic acid);
atrix; FGF-2, ﬁbroblast growth
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Perlecan is a large multi-domain heparan sulfate proteoglycan
(HSPG), which is found in basement membranes and the pericel-
lular environment [1]. The perlecan protein core (mass 470 kDa)
consists of ﬁve distinct domains. Domains II – V display homology tothe low-density lipoprotein receptor, laminin A chain, neuronal cell
adhesion molecule and epidermal growth factor [2]. The N-terminal
domain, domain I, is the main region of glycosaminoglycan
substitution, with a cluster of three attachment sites; an additional
two potential attachment sites exist on domain V [3,4]. Endothelial
cell-derived perlecan is substituted exclusively by heparan sulfate
(HS) at the domain I attachment sites [5]; chondroitin sulfate and
keratan sulfate variants have also been isolated from chondrogenic
and epithelial cell sources [6]. Perlecan is the major HSPG expressed
in the vascular wall and plays a key role in vascular homeostasis via
the stabilization and organization of vascular extracellular matrix
(ECM), and the regulation of adhesion, differentiation and prolifer-
ation of vascular cells [4,7]. These functions are mediated by
interactions of its protein core and HS chains with a variety of
extracellular matrix molecules, growth factors and adhesion
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embryonically lethal and associated with cardiovascular malforma-
tions and rupture of the heart and large blood vessels [8].
Atherosclerosis is a multi-factorial disease characterized by the
accumulation of lipids in the artery wall and chronic inﬂammation
[9]. Lesions contain large numbers of activated monocytes and
macrophages that are capable of generating reactive oxidants, and
it has been demonstrated that human atherosclerotic lesions, of all
degrees of severity, contain oxidized lipids and proteins. The levels
of these materials are signiﬁcantly elevated, and antioxidant levels
signiﬁcantly decreased, compared to healthy tissue (reviewed [10]).
Previous studies have shown that the majority of oxidative damage
to proteins detected in atherosclerotic lesions is associated with
ECM, rather than intracellular, proteins [11]. The contribution of
oxidative damage to vascular ECM to the progression of athero-
sclerosis is currently unclear, however it may be of considerable
importance. Modiﬁcation of the ECM of the artery wall is believed
to play a key role in both the development of atherosclerosis [12],
and the subsequent rupture of lesions, which is the major cause of
heart attacks and strokes [13]. The composition of the ECM within
the artery wall alters during lesion development, and is markedly
different at site of lesion erosion and rupture, with alterations in
the type and distribution of proteoglycans, collagens, and hyalur-
onan [14–16]. These changes in composition and properties may
contribute to endothelial cell loss and dysfunction, altered vascular
smooth muscle cell phenotypes and a decrease in the mechanical
stability of the lesion cap, thereby increasing the propensity of
lesions to undergo rupture. Notably, perlecan has been shown to
play a key role in modulating smooth muscle cell proliferation and
migration, a key feature of developing lesions and a major response
to vascular injury [17].
Considerable evidence supports a role for peroxynitrite (ONOO-/
ONOOH; this equilibrium mixture is termed peroxynitrite from
hereon) in the initiation of oxidation in atherosclerotic lesions and
ECM modiﬁcation (reviewed in [18]). Peroxynitrite is generated as a
result of the diffusion-controlled reaction (k ca. 7×109 M-1 s-1 [19])
of superoxide anion radicals (O2•-; generated by the respiratory burst
of activated leukocytes) with nitric oxide radical (•NO, generated by
the inducible nitric oxide synthase enzyme of macrophages) [20].
Other sources of O2•- and •NO present at sites of inﬂammation, such as
in atherosclerotic lesions that may also contribute to peroxynitrite
formation, include the activities of xanthine oxidase [21] and
endothelial nitric oxide synthase [22]. Considerable data supports
an increased rate of generation of these radicals, and
hence peroxynitrite, at sites of inﬂammation, including within the
diseased artery wall [20]. Thus extensive antibody staining for 3-
nitrotyrosine (3-nitroTyr), a stable modiﬁcation to Tyr residues
formed on exposure to peroxynitrite and other reactive nitrogen
species, has been detected throughout human atherosclerotic lesions
[23], and high- and low-density lipoproteins isolated from athero-
sclerotic lesions contain elevated levels of 3-nitroTyr when com-
pared to circulating lipoproteins [24,25].
Perlecan is likely to be an important target for damage by
peroxynitrite in the vascular wall, however the effects of this oxidant
on its structure and function are unknown. Data obtained with
isolated glycosaminoglycans, and intact ECM, indicate that HS chains
of perlecan are potential targets for modiﬁcation and fragmentation
by peroxynitrite. Thus, peroxynitrite can fragment isolated glycos-
aminoglycan chains (e.g. [26–28]), with this occurring in a site-
speciﬁc manner as a result of damage being induced by both
hydroxyl (HO.) and carbonate (CO3-.) radicals (but not to any great
extent by the peroxynitrite anion or nitrogen dioxide radical; NO2. )
[27,28]. Treatment of cell culture-derived matrix or isolated arterial
matrix with peroxynitrite results in the release of matrix fragments
that include both protein and carbohydrate components [29],
consistent with damage to perlecan. Concomitant generation of 3-nitroTyr in ECM proteins was observed [29], however the suscepti-
bility of perlecan to this modiﬁcation and the potential roles of
protein versus HS modiﬁcation in the degradation of this target is
unclear. Perlecan is also implicated as a target for the myeloperox-
idase-derived oxidants HOCl and HOBr [11,30,31], and recent studies
have established that HOCl can selectively modify and functionally
impair the cell adhesive function of the protein core, without
impairing the ability of its heparan sulfate chains to promote FGF-2-
dependent cellular proliferation [32].
To further elucidate the potential role of damage to perlecan by
peroxynitrite in vascular disease, the mechanisms and functional
consequences of exposure of human arterial endothelial cell-
derived perlecan (the major proteoglycan component of the
arterial subendothelial matrix), to peroxynitrite have been exam-
ined in detail. In particular, these studies have sought to resolve the
role of damage to the protein versus the HS chains, the potential
role of bicarbonate and reaction pH in modulating these reactions,
and whether such oxidant damage alters the biological activities of
this important vascular macromolecule.
Materials and Methods
Chemicals
Solutions were prepared using water puriﬁed through a four-stage
Milli Q system (Millipore-Waters) treated with washed Chelex resin
(Bio-Rad) to remove contaminating trace metal ions. pH control was
achieved using phosphate buffer (0.1 M), with pH adjustments made
using sodium monophosphate (0.1 M), sodium diphosphate (0.1 M),
or small quantities of concentrated HCl or NaOH.
Peroxynitrite was synthesized as previously [33]. Stock concen-
trations were determined spectrophotometrically using ε302 nm
1670 M-1 cm-1 [33]. Stock solutions of peroxynitrite anion (pH ca.
12) were prepared by dilution of the synthesized material into 0.1 M
NaOH. Due to the high concentration and pH of the stock solutions,
small volumes were added to strongly buffered solutions to
minimize pH changes; the reported pH values are determined for
the ﬁnal reaction mixtures. “Decomposed” peroxynitrite (dONOO)
was prepared by incubation overnight at 37 °C in 0.1 M phosphate
buffer, pH 6.
Cell culture
Human coronary artery endothelial cells (HCAECs) were cultured
in HCAEC GrowthMedium (Cell Applications) at 37 °C in a humidiﬁed
atmosphere containing 5% CO2. Cell-conditioned medium was
aspirated from near conﬂuent ﬂasks of cells and stored at -80 °C, for
subsequent perlecan puriﬁcation. For cell adhesion studies, cells were
cultured to approximately 90% conﬂuence, washed with PBS (pH 7.4)
containing 1 mM MgCl2/1 mM CaCl2 then incubated with 1% trypsin
for 3 min at 37 °C. Cell-conditioned media was added to neutralize
trypsin. Cells were washed twice with Medium-199 (Sigma) contain-
ing 1% BSA and resuspended in Medium-199 containing 1% BSA at a
cell concentration of 2.5×105 cells mL-1.
BaF3 cell culture
The ability of perlecan to promote cellular proliferation in
response to exogenous ﬁbroblast growth factor-2 (FGF-2) was
investigated using a heparan sulfate proteoglycan-deﬁcient myeloid
cell line (BaF3) expressing the FGF receptor isotype 1c (FGFR1c),
essentially as described previously [34]. Brieﬂy, BaF3 cells (105 cells
mL-1) were incubated in RPMI-1640mediumwith perlecan (1.25 nM)
or heparin (0.3 – 30 nM) in the presence of FGF-2 (0.3 nM) for 72 h at
37 °C and proliferation was then determined by the MTT assay using
CellTiter 96® AQueous One Solution (10% v/v, 6 h, 37 °C).
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Perlecan was puriﬁed from HCAEC conditioned medium by DEAE
chromatography followed by anti-perlecan (CSI-071, AbCam) afﬁnity
chromatography as described previously [5,34,35]. Perlecan core
protein concentrations were determined using a Coomassie Plus
microplate assay with BSA standards. Perlecan concentrations were
calculated using a core protein molecular mass of 470 kDa.
Oxidant and endoglycosidase treatment of surface-adsorbed
and soluble perlecan
Perlecan (10 - 32 nM, 4.7 μgmL-1, 50 μL) was absorbed from PBS onto
wells of 96-well microtitre plates (high-binding polystyrene, Greiner
BioOne; or polyvinyl chloride, BD Biosciences) for 16 h at 22 °C. This
surface-adsorbed material was incubated with fresh and decomposed
peroxynitrite (1 – 10 μM) for 20 min at 22 °C. Oxidant/perlecan
molar ratios in these experiments were 100 – 1000 (equivalent to 0.21 -
2.1 μmoles oxidant per mg protein) with surface absorption assumed to
be quantitative. Enzymatic digestion of perlecan was carried out using
heparinase III (0.025 UmL-1; Ibex) in PBS, pH7.2, for 16 h at 37 °C. Soluble
perlecan (100 – 300 nM) was subject to oxidation by peroxynitrite, and
enzymatic digestion with heparinase III, in a similar manner.
Enzyme-linked immunosorbent assays (ELISAs)
Wells of microtitre plates containing surface absorbed perlecan were
blocked with 0.1% casein in PBS and probed with mouse monoclonal
antibodies (mAbs) against HS (HepSS-1, 2 μg mL-1; 10E4, 2 μg mL-1;
JM403, 4 μg mL-1; Seikagaku), perlecan domain I (CSI-076, 3.3 μg mL-1;
AbCam), perlecan domain III (7B5, 2 μg mL-1; Zymed Laboratories)
perlecan domain V (CSI-074, 2 μgmL-1; AbCAm); and 3-nitroTyr (HM11,
2 μgmL-1, Zymed Laboratories). Detection of the immune complexeswas
performed using a biotinylated anti-mouse secondary antibody (1:1000,
GE Biosciences) with streptavidin-conjugated horseradish peroxidase
(1:500, GE Biosciences) and ABTS (KPL).
Measurement of protein carbonyls
Protein carbonyl formation was measured using a Protein
Carbonyl Enzyme Immuno-Assay kit (Biocell Laboratories Inc.).
Samples of soluble perlecan treated with peroxynitrite were concen-
trated by trichloroacetic acid precipitation, and derivatized with 2,4-
dinitrophenylhydrazine (DNPH) prior to measurement of protein
carbonyls by ELISA as described previously [36].
SDS-PAGE and immunoblotting
SDS-PAGE was carried out using 3-8% NuPAGE® Tris acetate gels
according to the manufacturer's instructions (Invitrogen), 2 μg
protein was loaded per well and HiMark® molecular mass standards
(Invitrogen) were used for reference. Gels were visualized using a
combined stains all-silver staining method [37].
For Western blotting studies, proteins were electroblotted onto
nitrocellulose membranes using an iBlot® transfer apparatus (Invitro-
gen). Membranes were blocked with 1% casein in PBS / 0.1% Tween
then probed with appropriate mouse mAbs (CSI-076, 2 μg mL-1; 10E4,
0.5 μg mL-1; 3-nitroTyr HM11, 1 μg mL-1). Detection of immune
complexes was performed using horseradish peroxidase-conjugated
anti-mouse Ig antibodies, ECL reagents and a ChemiDoc XRS image
acquisition system.
Cell adhesion assay
Adhesion of endothelial cells to polystyrene microtitre plates
coated with perlecan (20 nM, 9.4 μg mL-1) or ﬁbronectin (20 nM,10 μg mL-1) was quantiﬁed after 2 h incubation with HCAECs
(2.5×105 cells mL-1, 50 μL) at 37 °C by staining with crystal violet as
described previously [5].
Cell proliferation assay
Proliferation of Baf-32 cells was monitored using the MTT assay.
Brieﬂy Baf-32 cells in RPMI medium (4×105 cells mL-1, 200 μL) were
mixed with native perlecan, or that subjected to oxidation by
peroxynitrite at oxidant/perlecan molar ratios of 100 and 1000 for
20 min at 22 °C (5 nM, 200 μL) and 0.3 nMFGF-2 in RPMI 1640medium
(400 μL), plated onto a 96-well plate for 72 h at 37 °C in a humidiﬁed
atmosphere containing 5% CO2. MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt) and an electron coupling agent, phenazine methosulfate were
added to each well and incubated for 6 h at 37 °C. The absorbance at
490 nm was measured and used to calculate cell proliferation.
FGF-2 binding
Binding of [125I]-labeled FGF-2 (50 μl; ca. 120 000 cpm well-1) to
surface-absorbed perlecan (32 nM, 15 μg mL-1) was quantiﬁed by
gamma counting as described previously [5].
Analysis of human atherosclerotic lesions
Aortae and aortae abdominalis were obtained from three autopsy
subjectswhodied of cerebral hemorrhage. Themorphology of the aortae
ranged from microscopically normal to pronounced atheroma contain-
ing calcium inclusions; the lesions were classiﬁed as types I/II and III/IV
using the Stary classiﬁcation system [38]. For classiﬁcation of lesion
types, lesions were stained with Oil-red O. The samples were obtained
within 12 h of death, as described previously [39] and immediately
frozen in a cryostat (Microm,Walldorf, Germany, MicromHM 500 OM),
supported by tissue freezingmedium (Tissue Tec OCT-compound,Miles,
Elkhard, Ind., USA). Serial cryosections (5 μm) were collected on glass
slides, air dried for 2 h at 21 °C, ﬁxed in acetone for 5 min at 21 °C and
stored at -40 °C until analyzed [40]. The following monoclonal or
polyclonal antibodies were used as primary antibodies: anti-nitrotyr-
osine (rabbit IgG,Millipore, 1:75 dilution), anti-human perlecan (mouse
mAb, clone 7B5, perlecan domain III, Zymed Laboratories, 200 µg/ml,
1:10 dilution) anti-human CD14 (mouse mAb recognizing monocytes/
macrophages, Serotec, 1:50 dilution), non-immune rabbit IgG (Sigma)
and non-immune mouse IgG (Sigma). The following polyclonal
antibodies (Jackson Dianova) were used as detection antibodies: goat
anti-rabbit cyanine-3 (Cy-3)-labelled IgG (1:300dilution) and goat anti-
mouse Cy-2-labeled IgG (1:300 dilution).
For double immunoﬂuorescence, the sections were re-hydrated
in PBS (pH 7.4), blocked with UV ultra block (Lab Vision) for 10 min
and incubated for a further 30 min with anti-nitrotyrosine antibody
diluted with antibody diluent (Dako). The samples were then
rinsed in PBS, and incubated with a Cy-3-labeled goat anti-rabbit
antibody for 30 min. The sections were subsequently incubated
with antibodies against perlecan or CD14 followed by incubation
with Cy-2-labeled goat anti-mouse antibody [41]. The sections were
incubated with DAPI (Partec; 1:1000 dilution) for 5 min, mounted
with Moviol (Calbiochem-Novabiochem, La Jolla, USA) and ana-
lyzed using a confocal laser scanning microscope in sequential
mode (Leica SP2, Leica Lasertechnik GmbH, Heidelberg, Germany),
using the 405 nm laser line for the excitation of DAPI, the 488 nm
laser line for the excitation of Cy-2, and the 543 nm line for Cy-3
respectively. Detection emission settings were: 410 - 470 nm (blue
staining) for DAPI, 500 - 540 nm (green staining) for Cy-2 and 560 -
660 nm (red staining) for Cy-3. All incubation steps were
performed in a dark moist chamber at 21 °C. Controls experiments
were performed by omission of the primary antibodies or by
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normal rabbit IgG.
Computational modeling of the reaction of CO3
•- with the protein core and
HS chains of perlecan
Modeling of the reaction of CO3•- with perlecan was carried
out using the SimBiology feature of Matlab (The Math Works Inc,
Natick, MA) using published abundance data for the amino acid and
HS composition of perlecan [42] and the following second-order rate
constants (M-1 s-1 at 22 °C, pH 7): 7×105 for disaccharide subunits of
heparan sulfate (based on data for the related polymer hyaluronan
[43]), 5.0×106 for Tyr (based on second order rate constants for
reaction of CO3•- with phenol [44]), 7.2×108 for Trp (data for Gly-Trp
[45]), 3.6×107 for Met [45], 4.3×106 for His (data for Gly-His [45]),
1.3×106 for cystine (based on data for GSSG [45]) and 9×104 for Arg
[45]. Rate constants for reaction of CO3•- with other amino acids are b
1×104 M-1 s-1 [45] and were not incorporated.
Statistical analysis
Statistical analyses were performed using GraphPad Prism, PC
version 4 (GraphPad Software). One- and two-way ANOVA were
performedwith post-hoc statistical analysis using the Tukey'smultiple
comparison test and Bonferroni post-tests, respectively. Statistical
signiﬁcance was assumed at Pb0.05.
Results
Modiﬁcation of the core protein and HS chains of intact perlecan by
peroxynitrite
Perlecan was puriﬁed from HCAEC and the presence of a full-
length protein core (470 kDa) and exclusive substitution by HS was
conﬁrmed as described previously [32]. The effects of exposure of
perlecan to peroxynitrite was explored by examining both the al-
teration in the binding of antibodies that recognize speciﬁc epitopes
on the protein core (domains I, III and V) and the HS chains, and
speciﬁc oxidation products (3-nitroTyr and carbonyls) that may
result from oxidative damage. Studies were carried out at both pH
7.4 and lower pH values (6, 6.5 and 7) that mimic those found at
sites of inﬂammation [46,47].
Treatment of surface-adsorbed perlecan with peroxynitrite at
a 1000-fold molar excess over the perlecan protein concentration
(2.1 μmol oxidant per mg protein) at pH 6.5 caused a signiﬁcant loss
(ca. 20%) in recognition of HS by antibody 10E4 whilst decomposed
peroxynitrite (dONOO) did not (Fig. 1A). In contrast, this oxidant
treatment did not impair recognition of HS by antibodies JM403 and
HepSS-1, which recognize different HS structures to antibody 10E4
(Figs. 1B, C). A signiﬁcant loss of epitope recognition (10 – 20%) was
also observed with the peroxynitrite-treated perlecan using anti-
bodies raised against core protein domain I (CSI-076, Fig. 1D),
domain III (7B5, Fig. 1E) and domain V (CSI-074, Fig. 1F). A
signiﬁcant loss in domain I epitope recognition was also observed
with dONOO, though the magnitude of this effect was signiﬁcantly
less than with the active oxidant (Fig. 1D). This may be due to the
formation of HNO2 on peroxynitrite decomposition; this compound
is known to induce slow nitrosative deamination of amine func-
tions on proteins [48]. As the anion form of peroxynitrite reacts
rapidly with CO2 to give an adduct species (ONOOCO2- ) with this
potentially modulating in vivo reactions [49], studies were also
carried out in the presence of bicarbonate (NaHCO3, 25 mM, a con-
centration that results in physiological CO2 levels). Inclusion of this
material in the incubation medium abrogated the effects of dONOO
and peroxynitrite on recognition of HS and protein core by all the
antibodies investigated (Fig. 1).As the chemistry of peroxynitrite (and formation of downstream
reactive products such as HO., CO3-. NO2. and HNO2) is inﬂuenced by pH,
the effects of reaction pH (6 – 7.5) on antibody recognition of perlecan
exposed to a 1000-fold molar excess of peroxynitrite were investigated
to mimic conditions at sites of inﬂammation (Fig. 2). Peroxynitrite
caused a signiﬁcant decrease in recognition of HS by antibody 10E4
at both pH 6 and pH 6.5, but at higher values no changes in antibody
binding were observed (Fig. 2A), and no changes in recognition were
observed with the other HS antibodies (JM403 and HepSS-1) at any of
the pH values tested (data not shown). In contrast, loss of recognition
of the protein core was observed at all pH values with the antibodies
against domain I (Fig. 2B), domain III (Fig. 2C) and domain V (Fig. 2D).
The greatest loss in antibody binding occurring at pH 6.5 for domain I
and III and at pH 6 for domain V. The presence of bicarbonate (25 mM)
abrogated the changes in antibody binding induced by peroxynitrite
at all the pH values examined.
3-NitroTyr, a long-lived product arising from oxidation of Tyr
residues by reactive nitrogen species, is widely used as a marker of
peroxynitrite exposure [50]. Exposure of surface-adsorbed perlecan to
100 – 1000-fold molar excesses of peroxynitrite at pH 7.5, resulted in
a concentration-dependent increase in 3-nitroTyr formation as
detected by ELISA (Fig. 3A). Only background levels of 3-nitroTyr
were detected with dONOO. In the presence of bicarbonate (25 mM),
exposure to increasing concentrations of peroxynitrite resulted in a
concentration-dependent increase in 3-nitroTyr levels, however the
levels of this product were signiﬁcantly lower than in the absence of
bicarbonate (Fig. 3A). The yield of 3-nitroTyr on perlecan after
exposure to a 1000-fold molar excess of peroxynitrite increased
with pH, with a 3-fold increase above background detected at pH 6,
and a 17-fold increase at pH 7.5 (Fig. 3B). Inclusion of bicarbonate
(25 mM) resulted in higher 3-nitroTyr levels compared to its ab-
sence at pH 6, whilst at pH 7 and above this trend was reversed
(Fig. 3B). Similar levels of 3-nitroTyr were detected (5 – 7.5 fold
higher than background) across the pH range in the presence of
25 mM NaHCO3 (Fig. 3B). Exposure of perlecan to a 1000-fold molar
excess of peroxynitrite at pH 7 also resulted in elevated levels of
protein carbonyls (ca. 3-fold greater), a generic marker of oxidative
damage, compared to native protein (Fig. 4).
Structural consequences of perlecan-modiﬁcation by peroxynitrite
Perlecan migrates as a diffuse band at ≥470 kDa on 3-8% NuPAGE
gels as detected by both Stains-all/silver staining (Fig. 5A; lane 1) and
recognition by the protein core domain III antibody 7B5 and the HS
antibody 10E4 (Figs. 5B, C; lane 1). Exposure of perlecan to increasing
molar excesses of peroxynitrite at pH 7 resulted in the formation of
aggregated material that only migrated slightly into the gel, consistent
with oxidative crosslinking of the protein core (Fig. 5A, lanes 2-4). These
materials were also recognized by protein core and HS antibodies
(Figs. 5B, C; lane 4). In contrast, perlecan treated with dONOO showed
similar electrophoreticmobility to the untreatedmaterial (Figs. 5A, B, C;
lane 8). Western blot analysis using the 3-nitroTyr antibody showed
that peroxynitrite treatment induced a dose-dependent increase in
antibody staining (Fig. 5D; lanes 2-4), with this predominantly
observed at the same gel position as the aggregated protein (Fig. 5A;
lanes 2-4). No staining for 3-nitroTyr was detected on treatment of
perlecan with dONOO (Fig. 5B, lane 8). In the presence of bicarbonate
the extent of recognition of 3-nitroTyr was signiﬁcantly increased, with
the antibody recognizing material with a broad range of molecular
masses (Fig. 5D; lane 4 vs. lane 5).
Potential role of the HS chains is modulating the extent of core protein
damage induced by peroxynitrite
The potential role of the HS chains on perlecan in modifying
oxidative damage was investigated by comparing native and
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moieties from the protein core. Loss of the HS chains on such
treatment (16 h incubation at 37 °C) was conﬁrmed with the HS
speciﬁc antibody 10E4, with this treatment resulting in a 80% loss of
recognition by the antibody compared to non-treated proteoglycan
(Fig. 6A). In contrast recognition of the perlecan core protein by
domain I (CSI-076) and domain III (7B5) antibodies was increased
by ca. 20%, probably due to an increased exposure of epitope sites
(Fisg. 6 B, C). Subsequent exposure of the heparinase III-treated
perlecan to peroxynitrite (1000-fold molar excess) at pH 6.5 had no
effect on recognition of perlecanbyantibody10E4, as expected (Fig. 6A),
but decreased antibody recognition of the perlecan core protein
domain I (antibody CSI-076) and domain III (antibody 7B5) by ca. 20%
(Figs. 6B, C)with this loss in recognition being of a similar extent to that
observed with the parent proteoglycan. No signiﬁcant difference in 3-
nitroTyr detection was observed between intact perlecan and hepar-
inase III-treated perlecan on exposure to peroxynitrite (Fig. 6D).
Heparinase III treatment of perlecan prior to electrophoresis
resulted in a shift in the main protein band to ca. 470 kDa (Fig. 5A;Fig. 1. Effect of peroxynitrite exposure on the recognition of native epitopes on perlecan by m
decomposedperoxynitrite (dONOO, 10 μM)orperoxynitrite (ONOO, 10 μM)at22 °C for 20 min
ofNaHCO3 (25 mM). The perlecanwas thenprobed byELISA usingmonoclonal antibodies (mAb
epitopes: (D) perlecan domain I (mAb CSI-076); (E) perlecan domain III (mAb 7B5); and (F)
proteoglycan ELISA signal, and are means±SEM of values obtained from triplicate wells from
signiﬁcance assumed at pb0.05; a different to perlecan control, b different to dONOO, * signiﬁlane 6), with this band recognized by the protein core domain III
antibody7B5 (Fig. 5B; lane6)butnot theHSantibody10E4 (Fig. 5C; lane
6), This is consistent with the generation of the full-length, unsub-
stituted (HS-free) perlecan protein core. Exposure of the HS-free
perlecan to a 1000-fold molar excess of peroxynitrite resulted in
decreased staining of the band at ca. 470 kDa, and an increase in the
amount of aggregated protein (Fig. 5A; lanes 6 vs. 7). The high-
molecular-mass band attributed to aggregated protein showed signif-
icant 3-nitroTyr formation, which was greater than that observed with
intact perlecan exposed to the same concentration of peroxynitrite
(Fig. 5B; lanes 4 vs. 7).
Computational modeling of the reaction of CO3
•- with the protein core and
HS chains of perlecan
Computational modeling of the effect of HS chains on the extent of
reaction of CO3•- with Tyr residues on the protein core of perlecan was
performed using literature abundance data and second-order rate
constants (see Materials and Methods). The kinetic model wasonoclonal antibodies. Surface absorbed perlecan (10 nM) was treated with buffer (Pln),
in0.1 Mphosphate buffer, pH6.5 in the absence (blackbars) andpresence (light greybars)
s) against HS epitopes: (A)mAb 10E4; (B)mAbHepSS-1; (C)mAb JM403 and protein core
perlecan domain V (mAb CSI-074). Data are expressed as a percentage of the untreated
n≥3 independent experiments. Data were analyzed by 2-way ANOVA, with statistical
cantly different to experiments carried out in the absence of NaHCO3.
Fig. 4. Formation of protein carbonyls, a generic marked of protein oxidation, on
perlecan exposed to peroxynitrite. Perlecan (100 nM) was exposed to peroxynitrite
(100 μM) in 0.1 M phosphate buffer, pH 7 for 20 min at 22 °C. Protein carbonyl
formation was measured by ELISA.
Fig. 2. Effect of reaction pH on peroxynitrite-induced modifcation of perlecan. Surface
absorbed perlecan (10 nM) was treated with peroxynitrite (10 μM) at 22 °C for 20 min
in 0.1 M phosphate buffer, pH 6 – 7.5 in the absence (black bars) and presence (light
grey bars) of NaHCO3 (25 mM). The perlecan was then probed by ELISA using mAbs
against HS epitopes; (A) mAb 10E4 and protein core epitopes; (B) perlecan core (mAb
CSI-076), (C) perlecan domain III (mAb 7B5) and (D) perlecan domain V (mAb CSI-
074). Data are expressed as % normal ELISA signal and are means±SEM of values
obtained from triplicate wells with n≥3. Data were analyzed by 2-way ANOVA, with
statistical signiﬁcance assumed at pb0.05, a different to perlecan control, b different to
dONOO, * effect of NaHCO3.
Fig. 3. Formation of the tyrosine oxidation product 3-nitroTyr on perlecan exposed to
peroxynitrite: (A) effect of oxidant concentration, and (B) effect of reaction pH. Surface
absorbed perlecan (10 nM) was treated in the absence (black bars) and presence (light
grey bars) of NaHCO3 (25 mM) for 20 min at 22 °C with (A) 0.1 M phosphate buffer, pH
7.5 containing 1 – 10 μM peroxynitrite (100 – 1000 molar excess of oxidant over
protein) or dONOO (10 μM) or (B) 0.1 M phosphate buffer, pH 6 – 7.5 containing 10 μM
peroxynitrite. The perlecan was then probed by ELISA using a mAb against 3-nitroTyr
(HM11). Data are expressed as a % of the control ELISA signal obtained with untreated
perlecan and are means±SEM of values obtained from triplicate wells with n≥3. The
absolute absorbance (at 405 nm) for the controls with no perlecan were ∼ 0.055, and
for native perlecan ∼ 0.09; those for the peroxynitrite-treated perlecan were up to 1.6
absorbance units. These data indicate that the level of 3-nitroTyr on the native perlecan
was very low. Data were analyzed by 2-way ANOVA, with statistical signiﬁcance
assumed at pb0.05; a/A: different to native perlecan in the absence or presence of
NaHCO3 respectively, * effect of NaHCO3.
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CO3•- for HS-free perlecan (10 nM) and native perlecan (10 nM) with
peroxynitrite (0.1 – 10 μM) in the presence of bicarbonate (25 mM)
(cf. Fig. 3A). The consumption of Tyr residues in native perlecan (i.e.
with HS chains present as a competing target) was expressed as a
percentage of that predicted for the HS-free perlecan (i.e. no
competing HS chains) at varying oxidant excesses. The yield of CO3•-
in this system was taken as 35% of the peroxynitrite concentration
[50]. This modeling predicts (Fig. 7) that the HS chains compete withthe Tyr residues on the protein core, with this effect becoming more
signiﬁcant with greater oxidant excesses, due to the majority of
reaction at low excesses occurring with Trp residues. Modeling was
also carried out with a lower rate constant for reaction of CO3•- with
tyrosine (5×105 M-1 s-1) to mimic potential steric and electronic
hindrance of the reaction of the oxidant radical with buried Tyr side-
chains (cf. data for a diminished reactivity of Trp residues in peptides
Fig. 5. Structural consequences of perlecan modiﬁcation by peroxynitrite. Perlecan (330 nM) in 0.1 M phosphate buffer, pH 7 (lane 1) was exposed for 20 min at 22 °C to
peroxynitrite at molar ratios of 250 (lane 2), 500 (lane 3), 1000 (lane 4), 1000 in the presence of 25 mM bicarbonate (lane 5), heparinase III for 16 h at 37 °C (lane 6),
heparinase III followed by 1000-fold molar excess of peroxynitrite (lane 7), and dONOO (lane 8), prior to separation on 3-8% Tris-acetate gels under reducing conditions for 1 h
at 150 V and subsequent western blotting to nitrocellulose. (A) Stains-all/silver stain of gel. (B) Western blot probed for 3-nitroTyr formation with mAb against 3-nitroTyr
(HM11). (C) Western blot probed for heparan sulfate epitopes with mAb 10E4. (D) Western blot probed for perlecan domain III with mAb 7B5. Position of molecular mass
markers are shown for reference: ◁ perlecan heparan sulfate, ◀ perlecan protein core.
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the HS chains for reaction with CO3•- was more marked (Fig. 7), as
evidenced by an even greater decrease in the extent of Tyr consumption
in the native perlecan compared to the HS-free perlecan at identical
oxidant doses.
Exposure of perlecan to peroxynitrite modulates its functional properties
The functional consequences of exposure of perlecan to peroxyni-
trite was examined by quantifying both its ability to bind human
endothelial cells (HCAEC), a protein core-dependent process, and the
promotion of FGF-2-dependent cellular proliferation, which is
dependent on the presence of intact HS chains. Binding of HCAEC to
the perlecan protein core was inhibited by pre-incubation of the
perlecan with a 1000-fold molar excess of peroxynitrite at pH 7.5
(Fig. 8) in both the presence and absence of 25 mMNaHCO3. At pH 6.5,
these treatments had no effect on cell adhesion.
Perlecan stimulated the proliferation of FGFR1c expressing Baf-32
cells in response to FGF-2 and this stimulation was partially abrogated
by prior treatment of the perlecan with peroxynitrite at pH 7.5
(Fig. 9A), with a decrease in cell proliferation of 13% and 20% with a
100-fold and 1000-fold molar excess of peroxynitrite respectively;
this was statistically signiﬁcantwith the 1000-fold excess. Exposure of
perlecan to peroxynitrite, at either pH 6.5 or 7.5, resulted in a decrease
in its ability to bind FGF-2 (Fig. 9B), with this effect being signiﬁcant at
pH 7.5.
Detection of perlecan and 3-nitrotyrosine epitopes in human atherosclerotic
lesions by double immunoﬂuorescence
Perlecan, which is a component of the basement membrane, was
detected underneath the endothelial cells lining the artery wall, as
expected (Fig. 10A). In arteries with advanced atherosclerotic lesions
(type III/IV) 3-nitrotyrosine epitopes were readily detected in the
basement membrane intima, in the vasa vasorum, and at lower levels
throughout the media and adventia. The signals from the perlecan and
3-nitrotyrosine showed marked co-localization in these lesions
(Fig. 10A). In type I/II lesions the intensity of the signals arising from
3-nitrotyrosine epitopes was faint, but that from perlecan was readily
detected (data not shown). The role of tissue monocytes macrophages
in the formation of the 3-nitrotyrosine epitopeswas examined by use of
a monoclonal anti-CD14 antibody. 3-Nitrotyrosine could not only bedetected in association with perlecan, but was frequently found to
colocalize with CD14-positive cells located with the intima of
atherosclerotic plaques from type III/IV lesions (Fig. 10B).
Discussion
In this study the effects of peroxynitrite, an oxidant reported to be
formed in atherosclerotic lesions [23–25] and at other sites of
inﬂammation [52], on the major basement membrane HSPG perlecan,
have been examined. It has been shown that this oxidant modiﬁes
both the core protein structure, as evidenced by decreased recogni-
tion by multiple antibodies that recognize speciﬁc epitopes and the
formation of both 3-nitroTyr and protein carbonyls, and the HS
chains (decreased recognition by an antibody that recognizes speciﬁc
HS sequences [53,54]). These changes occur in a dose-dependent
manner and are modulated by the reaction pH and the presence of
bicarbonate. The speciﬁc core protein epitopes recognized by the core
protein and HS antibodies have been characterized previously [53–
56]. Evidence for the in vivo formation of peroxynitrite-modiﬁed
perlecan has been obtained by double immunoﬂuorescence studies
of advanced human atherosclerotic lesions, where intense co-
localization of perlecan and 3-nitrotyrosine epitopes has been
detected in the intimal region. These epitopes also co-localize with
CD14-positive cells, implicating tissuemacrophages – a known source
of peroxynitrite [50] - in the generation of this damaged material. The
localization of damaged perlecan with CD14-positive cells may be of
particular importance as macrophage-rich sites are associated with
weakening of the cap of atherosclerotic lesions and subsequent
rupture [57]. Modiﬁed perlecan has also been reported previously in a
study of human asthmatic tissue samples [58], but the nature and
source of the modiﬁcations were not examined.
The three HS antibodies used in the ELISA studies to probe the
effect of peroxynitrite on perlecan structure recognize distinct
domain structures in this polysaccharide. HepSS-1 recognizes
predominately N-sulfated domains, JM403 binding is dependent
on N-unsubstituted glucosamine residues and 10E4 recognizes a
sequence containing N-acetylated and N-sulfated glucosamine and
an N-unsubstituted glucosamine residue [53,54]). The selective loss
of 10E4 recognition, but not that of the other two antibodies
suggests that structures present within the sequence recognized by
10E4 may be particularly susceptible to damage by peroxynitrite.
These data are consistent with previous studies which have shown
Fig. 6. Effect of removal of the heparan sulfate (HS) chains of perlecan on modiﬁcation
induced by peroxynitrite. Surface absorbed perlecan (10 nM, Pln) was treated with
0.025 IU mL-1 heparinase III (HSase) for 16 h at 37 °C prior to exposure to peroxynitrite
(10 μM, ONOO) in 0.1 M phosphate buffer, pH 6.5 for 20 min at 22 °C. The perlecan
was then probed by ELISA using (A) mAb 10E4 (B) perlecan core (mAb CSI-076),
(C) perlecan domain III (mAb 7B5) and (D) 3-nitroTyr (HM11). Data are expressed as
% normal ELISA signal and are means±SEM of values obtained from 6 wells,
representative data shown. Data were analyzed by 1-way ANOVA, with statistical
signiﬁcance assumed at pb0.05, a different to perlecan control, b different to
peroxynitrite, c different to perlecan exposed to heparinase III.
Fig. 7. Computational modelling of the reaction of CO3•- with the protein core and
heparan sulfate chains of perlecan. Modeling of the reaction of CO3•- with native and HS-
free perlecan (10 nM) was carried out using literature abundance data and second-
order rate constants (see Materials and Methods) at various molar excesses (0.1 –
10 μM) of perlecan and assuming a 35% yield of CO3•-. Data are presented as the
predicted consumption of Tyr residues in native perlecan, expressed as a percentage of
the predicted consumption of Tyr residues in HS-free perlecan, using both the literature
rate constant for reaction of CO3•- with phenol, and a 10-fold lower value to simulate
steric and electronic effects on the reaction of CO3•- with buried Tyr residues. In both
systems, themodel predicts less loss of Tyr residues in the presence of HS chains than in
their absence (i.e. the HS chains act as a competitive target for CO3•-), with this effect
being more marked at higher oxidant excesses.
Fig. 8. Effect of perlecan modiﬁcation by peroxynitrite on human coronary artery
endothelial cell adhesion. Surface absorbed ﬁbronectin (20 nM) and perlecan (20 nM)
were exposed to peroxynitrite (ONOO, 20 μM) or dONOO (20 μM) in 0.1 M phosphate
buffer, pH 6.5 or pH 7.5, in the absence and presence of NaHCO3 (25 mM) for 20 min at
22 °C. The adhesion of endothelial cells (HCAECs) was measured by staining of bound
cells with crystal violet and expressed as a percentage of adhesion to surface-adsorbed
ﬁbronectin. Data are means±SEM of values obtained from six separate wells from a
single assay, representative of three. Data were analyzed by 2-way ANOVA, with
statistical signiﬁcance assumed at pb0.05, a different to perlecan control, b different to
dONOO.
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peroxynitrite-derived radicals, and in particular HO. (and CO3-. when
the reactions are carried out in the presence of bicarbonate) [27,28].
The results obtained in the current study are also consistent with
previous studies in which cell culture-derived ECM samples weretreated with peroxynitrite; in these experiments damage to both
the protein and carbohydrate components was detected, though
it was unclear whether the carbohydrate damage arose from free
(e.g. hyaluronan) or protein-bound (proteoglycan or glyco-protein)
species [29].
Damage by peroxynitrite to globular proteins [59], and isolated
glycosaminoglycans [27,28], has been shown previously to be pH
dependent in the absence of bicarbonate. This is believed to arise from
the greater reactivity of ONOOH (or species derived from it, such as HO.
and NO2. ) when compared to ONOO-. This is consistent with the data
obtained here for the HS chains (Fig. 2), with a greater loss of recog-
nition of the epitopes recognized by antibody 10E4 at pH 6 and 6.5,
than at pH 7 or 7.4 (Fig. 2). In contrast, there was no detectable pH
Fig. 9. Effect of perlecan modiﬁcation by peroxynitrite on Baf-32 cell proliferation and
binding of FGF-2. (A) BaF3 cells (expressing FGF receptor 1c) were incubated with
perlecan and FGF2 and the relative amount of growth was measured as described in the
methods section. (B) Surface absorbed perlecan (32 nM, black bars) was exposed to
peroxynitrite (ONOO, 32 μM, white bars) or dONOO (32 μM, light grey bars) in 0.1 M
phosphate buffer, pH 6.5 or pH 7.5 for 20 min at 22 °C. The extent of [125I]-labeled FGF-2
binding after 2 h incubation at 22 °C was quantiﬁed by gamma counting. a signiﬁcantly
different to untreated perlecan control.
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antibodies CSI-076, 7B5andCSI-074 (Fig. 2), althoughhigher yields of 3-
nitroTyr were detected at higher pH values (Fig. 3, black bars). These
differences may reﬂect alterations in the extent of attack at the HS
chains relative to the protein, as the pH of the reaction systems changes,
with a greater extent of reaction occurring at theHS chains compared to
the protein core at lower pH values (6.0, 6.5) and the inverse at higher
pH's. The higher levels of 3-nitroTyr detected at higher pH values are
consistent with the greater ease of oxidation of Tyr residues due to the
higher concentrations of the (deprotonated) phenolate anion.
Previous studies have provided evidence for enhanced damage
to globular proteins in the presence of bicarbonate, with this being
manifested as an enhancement in the yield of 3-nitroTyr (e.g. [60]).
This has been proposed to arise, at least in part, from the formation
of the peroxynitrite-carbonate adduct (ONOOCO2-). The formation of
this species is pH dependent, as it requires ONOO-, and subsequent
decomposition yields both NO2. and CO3-. [60,61]. The higher yield of
3-nitroTyr has been ascribed to the selective oxidation of Tyr
residues by CO3-., with the resulting phenoxyl radical undergoing
dimerization with NO2. to give 3-nitroTyr [61]. In contrast to these
previous reports, with perlecan the presence of bicarbonate di-
minished the extent of damage. Thus, the losses of antibody
recognition induced by peroxynitrite were lower in the presence of
bicarbonate than in its absence (Figs. 1 and 2), and higher yields of
3-nitroTyr were detected in the absence of bicarbonate, compared
to its presence (Fig. 3). These differences between globular proteins
and perlecan may arise, at least in part, from the relatively high
reactivity of CO3-. with the HS chains (cf. k 7×105 dm3 mol-1 s-1 for
reaction with the related glycosaminoglycan, hyaluronan [43])
compared to reaction with most protein side chains, with theexception of Tyr and Trp residues [62]. The presence of these
alternative targets for CO3-. (and to a lesser extent NO2. , which reacts
with hyaluronan at a lower rate [63]) appears to divert a signiﬁcant
proportion of the initial oxidant from damage to the protein core, to
the HS chains; this conclusion is supported by the computational
modeling data carried out with native and HS-free perlecan (Fig. 7).
A major biological function of perlecan, present as a component
of ECM, is its interaction with growth factors and adhesion
molecules, with this playing a major role in the adhesion, dif-
ferentiation and proliferation of associated cells. Thus arterial wall
proteoglycans play a major role in cell adhesion and function [64],
processes that are perturbed during the development of athero-
sclerosis. Adhesion of human endothelial and vascular smooth
muscle cells to human perlecan has been investigated, with this
shown to be dependent on the protein core [5]. Attempts to
determine the site of attachment (through the use of recombinant
perlecan domains) have been unsuccessful [5]; in contrast, with
mouse perlecan cell interaction occurs via β1 and β3 integrins, with
binding partially dependent on a RGD motif (absent in human
perlecan) localized to the C-terminus domain V [65]. In the light of
this previous data, and the observed modiﬁcation of the protein
core of perlecan by peroxynitrite, it was of interest to determine
whether oxidant exposure modulated this function of perlecan.
There was a slight but signiﬁcant reduction in the amount of cell
adhesion to the protein core when it was treated with peroxynitrite
at pH 7.5, but not at pH 6.5. Decomposed oxidant did not have this
effect. Interestingly, treatment with peroxynitrite at pH 7.5 in the
presence of bicarbonate, did not reverse the effect of peroxynitrite
(Fig. 8).
A second major function of perlecan is the binding of growth
factors [3,34]. Fibroblast growth factor-2 (FGF-2) associates with
perlecan through its HS chains [34,66] with interaction occurring
via short, highly-sulfated regions of the HS chains linked to domain
I of the protein core [7,56]. This association may protect FGF-2
from proteolytic degradation [67]. Previous studies have reported
that subtle changes in HS structure can modulate growth factor
binding and have profound biological effects [34]. Treatment with
peroxynitrite at pH 6.5 had no signiﬁcant effect on the ability of the
HS to signal via the FGF receptors, whereas at pH 7.5 a small, but
signiﬁcant decrease was observed (Fig. 9). This decrease is con-
sistent with the observed decrease is recognition of 10E4 epitopes
by approximately 20%. The ability of perlecan to stimulate FGF-2-
dependent cellular proliferation not only requires a capacity to bind
FGF-2, but also to form a ternary complex with the cognate cell
surface receptor [34]. In experiments with FGFR-1 expressing Baf-
32 cells, this biological activity of perlecan was signiﬁcantly
impaired (Fig. 9). Together these data indicate that oxidation of
the HS chains on perlecan may be of functional signiﬁcance.
Overall these studies show that peroxynitrite, an oxidant widely
believed to be generated at sites of inﬂammation, can modify the
structure of the HS proteoglycan perlecan, by altering both the
protein core and the HS chains, in a concentration-, pH- and bicar-
bonate-dependent manner. Damage to the HS chains by peroxyni-
trite was greater at pH 6 and 6.5 than at pH 7 or 7.4, with this
modiﬁcation being markedly inhibited by the presence of bicarbon-
ate. In contrast, damage to the protein core, as evidenced by loss
of native epitope recognition did not show this pH effect, and higher
yields of 3-nitroTyr were detected at pH 7.5 and 7 compared to
lower pH values. This damage to the protein was also markedly
diminished by the presence of bicarbonate. Decomposed peroxyni-
trite showed only minor effects. These changes to the protein and
HS chains resulted in higher levels of protein carbonyls, and the
formation of both lower- and higher-molecular mass species,
consistent with fragmentation and (to a greater extent) aggregation
of the proteoglycan. These oxidant-mediated effects resulted in
altered human endothelial cell binding to the proteoglycan and
Fig. 10. Double immunoﬂuorescence staining for perlecan, 3-nitrotyrosine epitopes and CD14-positive cells in human atherosclerotic lesion sections. Frozen sections (5 μm) of
human atherosclerotic lesions were incubated with monoclonal or polyclonal primary antibodies: anti-nitrotyrosine (rabbit IgG), anti-human perlecan (mouse mAb, clone 7B5,
perlecan domain III) anti-human CD14 (mouse mAb), non-immune rabbit IgG and non-immune mouse IgG, and subsequently the following detection antibodies: goat anti-rabbit
cyanine-3 (Cy-3)-labelled IgG or goat anti-mouse Cy-2-labeled IgG. DAPI was used to image cell nuclei. Images were acquired as described in the Materials and Methods. A) Heavily
thickened intima of an artery with a type III/IV lesion. Epitopes for 3-nitrotyrosine (red signal) show marked co-localization with perlecan (green) present in the basement
membrane of the endothelium (arrow) as well as with those of the vasa vasorum (dotted arrow). B) The signal for 3-nitrotyrosine (red) was frequently co-localized with CD14-
positive cells (macrophages, green). The red signal for nitrotyrosine underneath the bulk of macrophages results frommultiple oblique sections through a vas vasorum. C) In sections
where the antibodies for perlecan/CD14 and for 3-nitrotyrosine were replaced with non-immune mouse IgG (control, green) and non-immune rabbit IgG (control, red), no staining
in the intima was observed. The faint background staining in the media (also observed when no primary or secondary antibodies were applied to the sections) results from elastic
membranes located in this area. Scale as indicated in the bottom images.
291E.C. Kennett et al. / Free Radical Biology & Medicine 49 (2010) 282–293altered cell proliferation and FGF2 binding. These functional
changes may be of signiﬁcance in vivo at sites of peroxynitrite
formation. This conclusion is supported by the marked co-
localization of 3-nitrotyrosine epitopes with perlecan and CD14-
positive (macrophage) cells in the intima of advanced human
atherosclerotic lesions.
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